Print  |  Font Size Change Font Size
Search naabt.org  

The National Alliance of Advocates
for Buprenorphine Treatment

Buprenorphine (Suboxone®, Subutex®3, Zubsolv™4, Bunavail) is an opioid medication used to treat opioid addiction in the privacy of a physician's office.1 Buprenorphine can be dispensed for take-home use, by prescription.1 This, in addition to the pharmacological and safety profile of buprenorphine, makes it an attractive treatment for patients addicted to opioids.2

Does insurance cover it?


Most insurance companies cover the medication itself. However many people choose to pay for it themselves to keep their condition private. There are some doctors that will only take cash. It is one of the many unfair aspects of this disease. It pays to shop around. A doctor can choose what if any insurance they will accept (in some states). Every week more doctors are certified to prescribe. Some patients start with the first doctor they can get an appointment with,then find a more reasonably priced one later.

 

In the United States most physicians in private practice are for-profit businesses. Our free enterprise system allows them to charge what they feel the market will bare and it is up to the individual physicians to accept or not accept private insurance. If you do have insurance, many companies will allow you to submit the claim yourself for direct reimbursement. If your plan covers behavioral health conditions demand they pay your claim. Some insurance companies still feel that they can discriminate against people with addictive disorders. Most states have laws requiring insurance plans to cover addiction treatment. HBO addressed this in a documentary

 

How do I know if I'm paying too much?

 

12/08



Back to FAQs

The Purpose of Buprenorphine Treatment:

To suppress the debilitating symptoms of cravings and withdrawal, enabling the patient to engage in therapy, counseling and support, so they can implement positive long-term changes in their lives which develops into the new healthy patterns of behavior necessary to achieve sustained addiction remission. - explain -

The National Alliance of Advocates for Buprenorphine Treatment is a non-profit organization charged with the mission to:

  1. U.S. Food and Drug Administration, FDA Talk Paper, T0238, October 8, 2002, Subutex and Suboxone approved to treat opiate dependence.
  2. Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04-3939. Rockville, Md: Substance Abuse and Mental Health Services Administration, 2004.
  3. Subutex Discontinued in the US market in late 2011.
  4. FDA approved 7/3/2013 see buprenorphine pipeline graphic
  5. Rejected by FDA 4/30/2013 - Future Unknown - Probuphine denied by FDA